Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Bristol-Myers Squibb is running a new early-stage trial to test how its drug BMS-986435 behaves in the body and how safe it is. The official title notes it is a Phase 1, single-dose study in people with normal liver function and those with mild or moderate liver problems, which helps shape future dose plans and expands the potential patient pool.
The study tests a single oral drug, BMS-986435, also known as MYK-224. The goal is to see how the drug moves through the body and whether liver function changes this pattern, while monitoring for any safety issues that could limit broader use.
The trial uses a structured design where patients are put into set groups rather than random ones. It runs in parallel arms with no blinding, so both doctors and patients know the treatment, and the main goal is to understand treatment dosing rather than to prove long-term benefit.
The study is listed as recruiting, with first submission in November 2025, showing it is still in the early setup and enrollment phase. The last update came on June 10, 2026, signaling recent activity and suggesting timelines for first data may still be several quarters away.
For investors, this update signals Bristol-Myers Squibb’s steady push to advance new assets, which can support long-term growth expectations for BMY, though near-term earnings impact is limited. Competitors may see this as another sign that large pharma is carefully de-risking pipeline drugs, which can support sector sentiment but is unlikely to move stocks sharply until data readouts.
The study remains active and updated, and investors can access more details and future changes on the ClinicalTrials portal.
To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.
